title: Tarka® (trandolapril/verapamil hydrochloride extended-release) overdose.
abstract: BACKGROUND
  Patients with fixed-dose combination product overdoses involving verapamil and trandolapril may present differently than sole calcium channel blocker (CCB) or angiotensin-converting enzyme inhibitor (ACE-I) overdose alone, and may have implications for the toxicological management. The ACE-I component may confound the traditional response to antidotal and supportive therapy recommended for CCB overdoses. In such cases, it may be prudent to manage the trandolapril component concurrently while administering traditional CCB antidotes.
  
  
  OBJECTIVE
  To report a probable case and review the toxicological management of a fixed-dose antihypertensive combination product toxicity involving verapamil and trandolapril (Tarka®).
  
  
  METHODS
  A 60-year-old man experienced dizziness and fell after ingesting five tablets of Tarka®. Eight hours later, he was found to be hypotensive and bradycardic. Therapy for CCB toxicity was initiated, including fluids, modified hyperglycemia-euglycemia insulin therapy, calcium chloride, activated charcoal, and glucagon. The patient's blood pressure and heart rate stabilized only after the administration and titration of dopamine and episodes of profuse vomiting in response to glucagon. The patient was transferred to the Cardiac Intensive Care Unit for further monitoring. He was considered stable to the point of all therapies being discontinued only 12 h post-ingestion. The patient was discharged 40 h after ingestion with no further sequelae.
  
  
  CONCLUSIONS
  Lack of familiarity with the components of fixed-dose combination products poses a problem during overdose situations and may confound the presentation and delay resuscitation and acute stabilization.
authors.affiliation: Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, New York 11219, USA.
authors.forename: Victor
authors.initials: V
authors.lastname: Cohen
authors.forename: Samantha P
authors.initials: SP
authors.lastname: Jellinek
authors.forename: Lydia
authors.initials: L
authors.lastname: Fancher
authors.forename: Geetanjli
authors.initials: G
authors.lastname: Sangwan
authors.forename: Menachem
authors.initials: M
authors.lastname: Wakslak
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Marquart
authors.forename: Cyrus
authors.initials: C
authors.lastname: Farahani
mesh_terms: D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D062787:Drug Overdose; D004638:Emergency Treatment / Q000379:methods; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy*; D007211:Indoles / Q000008:administration & dosage / Q000506:poisoning*; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014700:Verapamil / Q000008:administration & dosage / Q000506:poisoning*
chemical_list: D003692:Delayed-Action Preparations; D004338:Drug Combinations; D007211:Indoles; C052035:trandolapril; D014700:Verapamil